Skip to primary sidebar Search this website Home Company Products News & Releases Careers Contact Us NEWS & RELEASES 2021-09-08 Xenikos Secures €40 Million in Convertible Debt Financing, Veloxis Pharmaceuticals Joins as Strategic Investor PDF Version NIJMEGEN, the Netherlands, Sept. 8, 2021 /PRNewswire/ — Xenikos B.V., a clinical-stage biopharmaceutical company currently developing a novel therapy for treating immune related disorders, announced today the closing of €40 million in convertible debt consisting of two equal tranches of €20 million. The financing was led by Veloxis Pharmaceuticals, with participation from existing investors, Medicxi, RA 2021-04-26 OSE Immunotherapeutics and Veloxis Pharmaceuticals Enter Into Global License Agreement to Develop, Manufacture, and Commercialize FR104, a CD28 Antagonist, in the Organ Transplantation Market Agreement expands Veloxis’ product portfolio and the continued commitment to improving the lives of transplant patients. OSE Immunotherapeutics to receive up to €315 million in potential milestones, including a €7 million upfront, and tiered royalties on sales. PDF Version Nantes, France – Cary, NC, United States, April 26, 2021 – 6:00PM CET — OSE Immunotherapeutics (ISIN: 2020-06-18 Transplant Therapeutics Consortium Receives Acceptance of Letter-of-Intent for iBox Scoring System as a Reasonably Likely Surrogate Endpoint from the Biomarker Qualification Program Collaboration between the transplant community, industry, and regulatory agencies develops biomarker aimed to streamline the development of novel therapies intended to improve long-term outcomes for kidney transplant recipients. PDF Version Cary, NC, June 18, 2020 — Critical Path Institute (C-Path) announced Wednesday, June 17, that its Transplant Therapeutics Consortium (TTC), of which Veloxis Pharmaceuticals is a member, 2020-02-17 Extraordinary General Meeting of Veloxis Pharmaceuticals A/S, 17 February 2020 Company Release no. 13/2020 PDF Version To: NASDAQ Copenhagen A/S Copenhagen, Denmark, 17 February 2020 Extraordinary General Meeting of Veloxis Pharmaceuticals A/S, 17 February 2020 Today, Veloxis Pharmaceuticals A/S’ Extraordinary General Meeting passed the following resolutions: The following persons were elected as members of the Board of Directors: Masaya Etoh Daisuke Matsuo Matthew Ryan Dumont 2020-01-29 Nasdaq Copenhagen A/S has Accepted Veloxis Pharmaceuticals A/S’ Request for Delisting of its Shares from Nasdaq Copenhagen A/S Company Release no. 12/2020 PDF Version To: NASDAQ Copenhagen A/S Copenhagen, Denmark, 29 January 2020 Nasdaq Copenhagen A/S has Accepted Veloxis Pharmaceuticals A/S’ Request for Delisting of its Shares from Nasdaq Copenhagen A/S As announced in company release no. 10/2020, Veloxis Pharmaceuticals A/S (“Veloxis”) has, upon request from Asahi Kasei Pharma Denmark A/S, requested Nasdaq 2020-01-24 Notice to Convene Extraordinary General Meeting Company Announcement no. 11/2020 PDF Version To: NASDAQ Copenhagen A/S Copenhagen, Denmark, 24 January 2020 Notice to Convene Extraordinary General Meeting Upon request from Asahi Kasei Pharma Denmark A/S, the board of directors of Veloxis Pharmaceuticals A/S, CVR no. 26 52 77 67 (the “Company”), hereby convenes an extraordinary general meeting in the Company to Announcement of Request for Delisting of Veloxis Pharmaceuticals A/S’ Shares from Nasdaq Copenhagen Company Release no. 10/2020 PDF Version To: NASDAQ Copenhagen A/S Copenhagen, Denmark, Friday 24 January 2020 Announcement of Request for Delisting of Veloxis Pharmaceuticals A/S’ Shares from Nasdaq Copenhagen Following company release no. 9/2020, in which Asahi Kasei Pharma Denmark A/S announced its decision to initiate a compulsory acquisition of the shares held by Veloxis Veloxis Pharmaceuticals A/S: Major Shareholder Notifications Company Release no. 8/2020 PDF Version To: NASDAQ Copenhagen A/S Copenhagen, Denmark, Friday 24 January 2020 Veloxis Pharmaceuticals A/S: Major Shareholder Notifications Veloxis Pharmaceuticals A/S (OMX: VELO) (“Veloxis”) hereby announces that it has received major shareholder notifications pursuant to chapter 7 of Consolidated act no. 931 of 06 September 2019 on Capital Markets, as amended Notice on Compulsory Acquisition to the Shareholders of Veloxis Pharmaceuticals A/S Company Release no. 9/2020 PDF Version To: NASDAQ Copenhagen A/S Copenhagen, Denmark, Friday 24 January 2020 Notice on Compulsory Acquisition to the Shareholders of Veloxis Pharmaceuticals A/S Pursuant to Sections 70-72 of the Danish Companies Act, Asahi Kasei Pharma Denmark A/S today announces its notice on compulsory acquisition to the shareholders of Veloxis Pharmaceuticals A/S 2020-01-23 Veloxis Increases Share Capital in Connection with Asahi Kasei Pharma Denmark’s Exercise of Warrants Acquired under the Public Tender Offer Company Release no. 7/2020 PDF Version To: NASDAQ Copenhagen A/S Copenhagen, Denmark, Thursday 23 January 2020 Veloxis Increases Share Capital in Connection with Asahi Kasei Pharma Denmark’s Exercise of Warrants Acquired under the Public Tender Offer On 17 January 2020, Asahi Kasei Pharma Denmark A/S (“Asahi Kasei Pharma Denmark”) announced the final result of the Page 1 Page 2 Page 3 … Page 11 Next Page » Primary Sidebar COMPANY Overview Management Team Compliance NEWS & RELEASES Xenikos Secures €40 Million in Convertible Debt Financing, Veloxis Pharmaceuticals Joins as Strategic Investor Sep 8, 2021 OSE Immunotherapeutics and Veloxis Pharmaceuticals Enter Into Global License Agreement to Develop, Manufacture, and Commercialize FR104, a CD28 Antagonist, in the Organ Transplantation Market Apr 26, 2021 Transplant Therapeutics Consortium Receives Acceptance of Letter-of-Intent for iBox Scoring System as a Reasonably Likely Surrogate Endpoint from the Biomarker Qualification Program Jun 18, 2020 READ MORE ©2021 All rights reserved. Veloxis Pharmaceuticals, Inc. US-UNB-2100005 7/21 Info@veloxis.com | 1-844-VELOXIS (835-6947), Monday-Friday, 9AM-7PM ET Sitemap | Contact | Privacy Policy | Disclaimer We'll assume you're ok with this, but you can opt-out if you wish. Cookie settingsACCEPT